Abstract A prospective study was performed between June1996 and December1997, to identify how general practitioners (GPs) in Belgium assess asthma severity and how they treat asthma according to their severity assessment. Three hundred and sixty-¢ve GPs included1376 already diagnosed and treated asthmatics.The GPs used a questionnaire providing data on patient demographics, aetiology of asthma, symptoms and medication use. The patients provided a complete diary card of day and night symptoms and morning and evening peak expiratory £ow rates during a 3-week period. Asthma severity as assessed by GPs was compared withthe severity according to the GINA guidelines. Along the same line, asthma treatment was evaluated according to the GP's assessment of severity and according to the GINA guidelines.Confronting the assessment of asthma severity by the GPs with the GINA criteria revealed that about 20% and 2% of the patients'asthma severity respectively were under-and over-estimated, respectively (using a discrepancy between GPs and GINA assessment of severity by 2 or more classes).Using the GINA criteria for treatment, only 37?5% of the patients seemed to be correctly treated.Taking a discrepancy between GINA assessment and treatment of two classes as an error, 2?3% and 23?4% of the asthmatics are over-and under-treated, respectively. In conclusion, this study provides evidence that GINA guidelines seem not to be adequately interpreted and implemented by GPs in Belgium. Improvement of the assessment of asthma severity is de¢nitely needed and may lead to more appropriate use of asthma medication.r 2002
INTRODUCTION
Asthma is a chronic in£ammatory disease of the airways which may cause signi¢cant morbidity and mortality if not managed optimally. The disease is associated with a range of symptoms, including cough, particularly at night, wheeze, di⁄culty breathing and chest tightness, which are important in diagnosis of the condition and assessing its severity. Probably even more important in the assessment of disease severity are objective measures of pulmonary function such as peak expiratory £ow rate (PEFR) and forced expiratory volume in 1sec (FEV 1 ).
Assessment of disease severity is therefore crucial to determining optimal treatment. A wide range of di¡er-ent classes of medication are available for the treatment of asthma and the selection of the optimal treatment or combination of agents is essential to ensure that the disease is well controlled. However, it is unclear how well the complexities of treatment options are implemented by physicians routinely managing patients with asthma, and it has been suggested that the current trends towards increased morbidity and mortality associated with asthma may well be due to under-diagnosis and undertreatment of the disease (1) .
In most countries, management of patients with asthma is largely performed by general practitioners (GPs). This may pose problems because of the complexity of the disease and the need to constantly monitor a patient's condition and adjust treatment if necessary to ensure that optimal disease control is achieved. Over the last decade various sets of guidelines, both national and international, have been published to assist physicians in the management of their asthma patients. These guidelines, such as those of the Global Initiative for Asthma (GINA) set out recommended management strategies according to the severity of disease, prior to any treatment (2) . However, it is unclear to what extent these guidelines are being used in clinical practice and the results of various previous studies suggest that GPs do not strictly implement them (3^7). This is of particular concern since the appropriate management of asthma is largely dependent on an accurate assessment of severity and appropriate prescription of medication. The present study investigated how accurately GPs assess the severity of disease in their asthma patients and whether their prescription of medication is appropriate to their assessment of disease severity.
METHODS
This prospective study started recruitment in June 1996 and enlisted the last patient in December1997.The study was approved by the Ethics Committee of the University Hospital Gasthuisberg (Leuven) and oral informed consent was obtained from all participating patients.
A total of 400 GPs from Belgium were contacted, 356 agreed to participate and were recruited into the study. The GPs were selected from a list of all practising GPs in Belgium based on a random sample strati¢ed for geographical area. Each GP taking part in the study was asked to complete a separate questionnaire for each of ¢ve consecutive patients with previously diagnosed and already treated asthma. The questionnaire requested the following information: (1) assessment of severity of disease; (2) details of the patient's asthma symptoms including types of exacerbations and limitation of physical exercise; (3) overnight PEFR variability; (4) percentage predicted PEFR, and (5) details of medication prescribed (Table 1) . Each patient included in the study was also asked to provide the following information: (1) complete a diary card of symptoms (day and night) for 21 days, and (2) perform morning and evening PEF measurements for 21 days. The disease severity of each patient was then checked by two pulmonologists (G.M.V. and P.D.V.) based on the criteria speci¢ed in the GINA guidelines (more speci¢cally day and night symptoms, PEFR (in % predicted) and PEFR variability, daily medication use). Their assessments were based on the data provided by the patients and their GPs.
Details of medication prescribed for each patient was also recorded in the GP's questionnaire (Table 1) . In addition to recording the class of medication (e.g. inhaled corticosteroid, short-acting b 2 -agonist, long-acting b 2 -agonist), the overall medication received by each patient was classi¢ed according to the GINA guidelines into four categories as detailed inTable 2.
Statistical analyses
A multivariate analysis was used to assess the diagnostic parameters that in£uenced the assessment of asthma severity by the GP. The correlation between diagnostic parameters and GP assessment of severity was further assessed by calculation of Spearman's correlation coe⁄-cients at a level of statistical signi¢cance of 1% (Po0?01). For data on ordinal scale, statistical tables were produced providing the absolute number and the percentage per category.
RESULTS

Patients demographics
A total of 1376 patients were included in the survey and data was obtained from 356 GPs, who thus each recruited on average 3?9 patients into the study.The mean patient age was 39?2 years (SD, 10?9 years; median, 39?9 years) and the ratio of male: female was approximate 1:1 (male, 51?8%; female, 47?6%; gender not recorded, 0?6%). Almost two-thirds of patients reported not previously 
Assessment of disease severity
According to the GP's assessment of the severity of disease, 30?5% of patients had intermittent asthma, 29?4% had mild persistent asthma, 31?4% had moderate persistent asthma and 8?7% had severe asthma. Analysis of possible correlations between the various information on disease severity and symptoms supplied by GPs and their assessment of severity indicated signi¢cant correlations (Po0?01according to two-tailed test) between GP's perception of disease severity and: number of symptoms per day, number of symptoms per night; % predicted PEFR; PEFR variability; in£uence on physical condition; and type of exacerbation. Values for Spearman's correlation coe⁄cient are shown in Table 3 .
A multivariate analysis revealed the GP's assessment of disease severity correlated most strongly with patient's daytime symptom score, suggesting that this is the parameter on which GP's most depend when assessing disease severity. This is further demonstrated in Fig. 1 which shows for each class of disease severity (according to the GP's assessment), the number of patients with continuous daytime symptoms, daily daytime symptoms and less frequent daytime symptoms. It seems that for each severity class, most of the patients in that particular class are classi¢ed correctly.
However, a lot of patients are misclassi¢ed, for instance patients with daily symptoms are also classi¢ed as intermittent or mild persistent asthmatics. A strong correlation was also observed between GP's assessment and the in£uence of disease on the patient's physical condition.
Assessment of disease severity by the pulmonologists according to the GINA guidelines revealed that respectively 16?9% of patients had (while already being treated) intermittent disease, 17?7% mild persistent disease, 32?6% moderate persistent disease and 32?8% severe disease (Table 4) .These values were compared with the GPs assessments and patients were regarded as misclassi¢ed if the discrepancy between the GP assessment and GINA assessment was by two or more classes (e.g. GINA assessment of intermittent and GP assessment of moderate or severe, or GINA assessment of severe and GP assessment of intermittent or mild, etc). Although GPs correctly estimate disease severity in 78% of patients, they under-estimate the severity of disease in about 20% of patients, and over-estimate disease severity in about 2% of patients. When only one GINA class discrepancy was used to assess over-or under-estimation of asthma severity, then, there was an under-and over-estimation respectively of asthma severity in about 52% and 12% of the cases, whilst only 36% were classi¢ed correctly.
Medication use
Information on medication use is shown in Table 5 . Inhaled corticosteroids and short-acting b 2-agonists were Analysis of the medication type according to the classi¢cation criteria described in the GINA guidelines revealed that 192 patients (14?5%) were only receiving step 1 medication, 752 (56?8%) were receiving step 2 medication, 272 (20?5%) were receiving step 3 medication and 108 (8?2%) were receiving step 4 medication.These data were further analysed to determine the disease severity of patients (as assessed by their GP) in each treatment group (Table 6 ). These data revealed that only 37?5% (497 out of 1324) were correctly treated according to the GP's assessment of disease severity and the GINA guidelines for treatment. This included 24?5% (99 out of 404) of patients with intermittent asthma, 64?2% (251 out of 391) of those with mild persistent asthma, 27?2% (113 out of 416) of those with moderate persistent asthma and 30?0% (34 out of 113) of those with severe persistent asthma. Slight to signi¢cant under-treatment, therefore, occurred in 29?6% (392 out of1324) patients and a further 32?9% (435 out of 1324) were being over-treated, according to the GP's assessment of disease severity. For example, 70?0% (79 out of 113) patients with severe asthma were under-treated, while 75?5% (305 out of 404) patients with intermittent asthma were probably overtreated (Table 6) .
Analysis of medication use according to disease severity as assessed by pulmonologists using the GINA guidelines also revealed that a signi¢cant number of patients were being under-treated.When a discrepancy between GINA assessment and treatment of two classes or greater is regarded as an error, 2?3% of patients are over-trea- ted and 23?4% are under-treated. These ¢gures increase to 19% over-treatment and 54?2% under-treatment if a discrepancy between assessment and treatment of only one or more classes is regarded as an error (Table 7) . Under-treatment occurred for instance in 55?3% (240 out of 434) patients with severe asthma and 16?2% (70 out of 432) of patients with moderate asthma (assuming an error of 2 or more classes between assessment and treatment). Over-treatment occurred in 11?8% (24 out of 223) patients with intermittent asthma and 3?0% (seven out of 235) of those with mild persistent asthma (assuming an error of 2 or more classes between assessment and treatment). This high level of under-treatment by
GPs is in agreement with their signi¢cant under-estimation of the severity of disease (in 29?6% of patients).
DISCUSSION
The results of this study suggest that GPs in Belgium largely depend on daytime symptoms and the patient's physical condition to assess asthma severity, rather than on all the parameters recommended by the GINA guidelines, although the GINA guidelines were already issued for a certain time and largely distributed amongst the GP's at the time of the study. Although in our study we have tried to classify already treated asthmatics according to the GINA guidelines, we are perfectly aware that GINA guidelines severity classi¢cation applies to symptoms and peak £ow before any treatment is given. Since most asthmatics are indeed being treated, it remains, therefore, di⁄cult to assess the severity of their asthma, when strictly holding on to the GINA guidelines.Therefore using current symptomatology together with PEFR measurements and the need for medication, may allow to further categorize disease severity in already treated asthmatics. Such an approach has previously been used by Liard et al., who demonstrated an under-estimation of the disease severity in about 27% of the patients (8) .
In our study, it was also shown that GPs tend to underestimate the severity of the disease (i.e. in approximately 20^52% of patients, according to one or two classes of discrepancy). The percentage of patients with moderate to severe asthma, as judged by the two pulmonologists, seems very high in our study (465%). This is certainly higher than what would be expected in an asthma population. The high percentage might result partly from an inclusion bias by the GPs. Indeed they may have included some of their worst asthmatics, although it had been asked to include successive patients.The best possible explanation, however, comes from the fact that the current medication use was included to classify patients, and, indeed, the study demonstrates that about 33% of the patients are over-treated, which may categorize them in a higher disease classi¢cation. As a consequence, this suggests GPs in Belgium do not strictly implement the guidelines. The reasons for this are not quite clear, but there are several possibilities, which will be discussed further.
Possibly as a result of this inadequate assessment of asthma severity, Belgian GPs tend to under-treat asthma, when compared to the GINA guidelines. The present study found that approximately 30% of patients are prescribed medication appropriate to less severe disease than their symptoms would warrant, as assessed by the GP. This is particularly the case for patients with moderate or severe asthma where 60% and 70% of patients, respectively, are under-treated. When asthma severity was assessed according to the GINA guidelines, 54% of patients were found to be receiving medication appropriate to less severe disease. Over-treatment was also observed in 2^19% of patients (according to either one or two classes discrepancy that was used). Such disparities between apparent disease severity and prescribed medication, e.g. patients with severe asthma only receiving b 2 -agonist relief medication; patients with intermittent asthma symptoms receiving systemic steroids, need to be addressed to ensure that patients' symptoms are well managed without unnecessary medication being prescribed.
Our results are in agreement with those from previous studies in other countries which have revealed poor implementation of national asthma guidelines. For example, one study of asthma prescriptions in six British general practices found that only 58% of patients were receiving asthma medication regimens that were consistent with those recommended by the British Thoracic Society 1 year earlier (7). Another U.K. study (4) found evidence to suggest that management by GPs with a particular interest in asthma (members of the GP in Asthma group) is closer to that recommended by asthma guidelines than for other general practitioners. A Greek study found that only 23% of primary health care physicians in Greece prescribed according to asthma guidelines (3). Instead, most primary health care physicians in Greece treat patients according to the recommendations of the pulmonologist who sees the patient initially. Thus, changes in asthma severity and response to medication seem not to be optimally monitored and medication may not be adjusted accordingly by the GP. A U.S. study of physicians' understanding of the National Heart, Lung and Blood Institute (NHLBI) asthma guidelines found that the mean score achieved by the108 physicians tested was 60%.The physicians tested were members of the Division of Pulmonary, Critical Care, and Occupational Medicine at the University of Iowa and included 31 asthma specialists. Asthma specialists achieved higher total scores (mean, 78%) but no groups scored well on estimating disease severity (means scores, 27^56%) (6) . This suggests that improvements in the national asthma guidelines in many countries may be appropriate to make them more easily understood and applied in a busy clinic. As a consequence, one possible explanation for non- adherence to the guidelines could be that GPs receive too many guidelines to know them all (GPs with a special interest in asthma do better) and furthermore that GINA guidelines are too complex to interpret and that it may also take too much time from a GP to establish the real asthma severity based on a thorough interview of the patient and the search for residual symptoms that could be tackled with other or add-on medication. This may explain a great deal of under-treatment. Conversely, we also have the impression that step-down is rarely used by GPs. If the patient feels well, the treatment is considered to be optimal, which may explain a great deal of over-treatment. To resolve this, a standard questionnaire such as the asthma control questionnaire (9) or the asthma severity score (10) could be used to analyse the patient's symptoms/asthma control and the need for step-up or step-down treatment.
Analysis of overall medication use in the present study revealed that approximately 70% of patients were receiving inhaled steroids. This is in agreement with GINA guidelines and suggests inhaled steroids are, on average, probably being prescribed correctly in Belgium. Similarly a study of users of asthma medications in Iceland found that of the patients aged16 years or older, 62% were prescribed inhaled corticosteroids (11) . In contrast, a Greek study found that inhaled corticosteroids constituted only 24% of asthma medications (3). However, this represented a signi¢cant improvement in prescribing practices over 3 years in which corticosteroid use increased by 10%, probably in response to better dissemination of guidelines. In another study performed in the European Community, only17^49% of the patients were on inhaled anti-in£ammatory drugs. The prevalence of anti-in£am-matory treatment was, however, positively related to the prevalence of nocturnal symptoms of asthma (12) . In a recently published study on asthma management in ¢ve European countries, the proportion of asthma patients receiving inhaled steroids varied between 31% in Germany to 58% in The Netherlands (13) . The high percentage of users of inhaled steroids in our study may represent another bias. Although GPs were asked to include successive patients with asthma, they may, however, have preferentially included asthmatics who were already being treated with inhaled steroids.
Although a rather large proportion of our patients were taking anti-cholinergics, we are fairly convinced that our patients were indeed asthmatics, based on the mean age (o40 years), the PEFR and variability, the fact that over 60% were never-smokers and above all, the knowledge that using anti-cholinergic agents for asthma (especially in combination with short-acting b 2 -agonists using the same inhaler device), is common practice in Belgium, although anti-cholinergics are not recommended as reliever medication by GINA.
According to the GINA guidelines, long-acting bronchodilators (e.g. inhaled/oral long-acting b 2 -agonists or oral slow release theophylline) should be used in conjunction with inhaled corticosteroids in patients with moderate and severe persistent asthma. In our study approximately 35% were using these type of drugs, which still represents an underusage of this class of medication, which should be used in at least all patients with moderate or severe asthma, (i.e. approximately 4 40% of all asthma patients). Especially the use of long-acting inhaled b 2 -agonists was very low in our study (9%) and may well account for a signi¢cant proportion of the observed under-treatment, however, the Belgian reimbursement criteria in use at the time when the study was performed may have contributed to this under-use.
More detailed analysis of the patients with severe asthma receiving oral corticosteroid therapy in our study, also revealed an under-usage of other therapies in this class of patients, especially long-acting inhaled or oral b 2 -agonists and even inhaled corticosteroids (leukotriene receptor antagonists were not yet available at the time), which might again have contributed to suboptimal management of patients with severe asthma requiring oral corticosteroid therapy (14) .
Assessing asthma severity not only depends on the questions asked by the physician, but also on the interpretation of the symptomatology by the patients themselves.The latter might also be another major reason for under-estimation of severity and, hence, under-treatment. This is clearly illustrated in the AIRE study, which describes the patients asthma insight and the clinical management of asthma in Europe. It was demonstrated in this particular study that approximately 50% of the patients reporting severe persistent asthma symptoms, considered their asthma to be under control and that 46% of the patients also reported daytime symptoms, whereas only 23% had taken inhaled steroids over the past 4 weeks (15). Furthermore, 50% of patients with severe disease perceived their asthma to be well controlled, although their reported quality of life was poor and their healthcare utilization was high (15) .
Not only symptom reporting and severity perception of the patient are important; there still remains the major problem of non-compliance as a cause of persistent asthma symptoms. For instance, in an Italian study only 65% of the patients who had received anti-asthma drug prescriptions declared they had taken all the drugs prescribed (16) . And in another recent study from our own group, the self-reported non-compliance was estimated as high as 35%, however, varying between 15 and 48%, depending on the clinical situation of the patients at the time (17) . In the present survey, no attempts were made to acknowledge the compliance, but it is estimated that there will have been a high rate of non-compliance since the study in fact represents real life.
In summary, the results of our study suggest that improvements in the assessment of asthma severity in Belgium are warranted (as is also the case in other parts of the world where this type of study has been done) and could lead to the more appropriate use of asthma medication. In particular, a better understanding of the various parameters (including rigid assessment of all possible symptoms (9,10) and pulmonary function criteria, which seem to be de¢nitely under-used (15) , which can be used to assess asthma severity and a better use of add-on therapies is required. Such improvements in the understanding of the disease and its treatment (as well by the physician as by the patient and other healthcare providers) should ensure that physicians carefully screen for asthma control, that asthma patients receive the optimum care they deserve and that they improve their compliance, which might result in fewer exacerbation episodes (18) , hospital admissions and asthma deaths (19) .
Since this study has been performed in Belgium (19961 997), the local reimbursement criteria for long-acting inhaled b 2 -agonists have changed, furthermore, new guidelines have been published and new therapies have become available (anti-leukotrienes), therefore, it is hoped that at the present time, assessing asthma severity as well as asthma treatment might have improved. This, however, will have to be demonstrated in a followup study.
